Curaleaf (OTCQX: CURLF) splits its stock and chases a US uplisting on rescheduling

Curaleaf (OTCQX: CURLF) is one of the largest cannabis companies in the world, and in 2026 it is moving fast to capitalise on the moment the entire industry has waited years for. US cannabis rescheduling is finally easing the punishing tax burden that has crushed operator profits, and Curaleaf has responded with a 1-for-3 reverse stock split, effective 5 June 2026, designed to lift its share price high enough to uplist onto a major US exchange. The reason the ticker is trending is this rare combination of a genuine regulatory turning point and concrete corporate action to seize it. For a retail investor landing on CURLF, the question is whether this is the start of a long-awaited re-rating for cannabis, or another false dawn in a sector that has disappointed before.

What does Curaleaf actually do and how does its US and European cannabis footprint work?

Curaleaf is an international cannabis company that cultivates, produces and sells both medical and adult-use cannabis products across multiple US states and a growing list of international markets. In the United States it operates as a vertically integrated multi-state operator, controlling cultivation, extraction, manufacturing and retail, with a portfolio of brands including Curaleaf, Select, Grassroots and Find. Internationally, it has built a distribution network spanning Europe, Canada and Australasia. The company is chaired and led by chief executive Boris Jordan and is based in Stamford, Connecticut.

What sets Curaleaf apart from many US peers is its scale combined with a genuine international footprint. Most US multi-state operators are trapped inside the patchwork of state markets because cannabis remains federally restricted, which blocks interstate commerce. Curaleaf’s investment in Europe, particularly its German medical cannabis operations, gives it a diversified growth engine that is not dependent solely on the slow grind of US state-by-state legalisation.

The implication is that Curaleaf is two businesses bolted together: a mature, cash-generative but slow-growing US operation, and a faster-growing international arm that is still small but expanding rapidly. That structure matters now because the US side stands to benefit most from rescheduling, while the international side provides the growth that US federal gridlock has long denied the sector. Understanding which engine is driving results in any given quarter is key to reading the stock.

Why does US cannabis rescheduling change the entire profitability picture for Curaleaf?

Rescheduling is the catalyst that underpins everything else. For years, US cannabis operators have been taxed under a provision of the federal tax code, known as Section 280E, that bars businesses dealing in federally controlled substances from deducting normal operating expenses. The result has been punitive effective tax rates that turned otherwise viable companies into chronic loss-makers. Curaleaf’s chief executive has described the rescheduling of medical cannabis as historic, framing it as a shift in the trajectory of the entire industry.

The financial significance is hard to overstate. Easing or removing the 280E burden would dramatically improve cash flow and profitability across the sector, because companies could suddenly deduct the expenses every normal business takes for granted. Curaleaf has already filed applications for registration with the Drug Enforcement Administration, positioning itself for the rescheduled environment, and management explicitly described the macro headwinds of the past three years turning into tailwinds.

The caveat is that rescheduling is a process, not a switch, and the details determine the payoff. Moving cannabis to a less restrictive schedule does not make it federally legal, and important constraints around banking, interstate commerce and state-level patchworks remain. The exact timing and mechanics of the tax relief flowing through to the income statement are still uncertain, and the sector has a long history of regulatory optimism that arrived later and smaller than hoped. The direction is genuinely positive, but the magnitude and timing are not yet locked in.

What is behind Curaleaf’s 1-for-3 reverse split and the plan to uplist on a US exchange?

The reverse split is the clearest sign of how seriously Curaleaf is taking this moment. On 5 June 2026 the company executed a 1-for-3 reverse stock split, consolidating its subordinate voting shares from about 699 million to roughly 233 million and tripling the per-share price in the process. Crucially, the company stated the split was done in consultation with US exchanges specifically to prepare for an uplisting, in direct response to rescheduling.

The strategic logic is about access to capital. Curaleaf currently trades over the counter in the United States under the CURLF ticker and on the Toronto Stock Exchange as CURA, venues that limit the pool of institutional investors willing or able to participate. An uplisting to a major US exchange, paired with a planned domestication that would move the company’s legal home from British Columbia to Delaware, would open the door to far larger institutional ownership, index inclusion and improved liquidity. A shareholder meeting on 22 June 2026 sits on the near-term calendar as part of this transition.

The implication is a clear sequence of catalysts: rescheduling created the opening, the reverse split prepared the share structure, and the US domestication and uplisting are the next steps to watch. However, reverse splits carry mixed signals, since they are often associated with struggling stocks trying to meet listing minimums, and the market reaction to the announcement was negative. The uplisting is a goal, not a certainty, and execution on the legal and regulatory steps still has to be delivered.

How is Curaleaf’s European expansion and the Four 20 Pharma buyout driving its growth?

While the US story dominates headlines, Europe is where Curaleaf is actually growing fastest. In the first quarter of 2026, international revenue rose about 35 percent year over year to US$47 million, far outpacing the roughly 2 percent growth in its domestic US business. Germany has been the standout, with medical cannabis demand expanding rapidly after regulatory liberalisation, and Curaleaf has leaned hard into that opportunity.

The clearest expression of that focus was completing the buyout of the remaining 45 percent stake it did not already own in Four 20 Pharma, a fully licensed German producer and distributor of medical cannabis, in April 2026. Taking full ownership of a cornerstone of Germany’s medical cannabis supply chain gives Curaleaf complete control of a high-growth asset in Europe’s most important market, and it deepens a footprint that competitors will struggle to replicate quickly.

The implication is that international growth is doing real work to offset a sluggish US market that suffers from oversupply and price compression in mature states. The trade-off is that the international segment is still small in absolute terms and currently dilutes margins, dragging on profitability even as it adds revenue. Europe is a genuine differentiator and a credible long-term growth driver, but it is not yet large enough to carry the whole company, and scaling it profitably is its own challenge.

How is the market pricing CURLF after the reverse split, and is the company profitable yet?

The valuation picture has to be read through the lens of the recent split. Curaleaf carries a market capitalisation of roughly US$2.7 billion, which the reverse split left unchanged even as it cut the share count to about 233 million subordinate voting shares and tripled the quoted price from around US$3.60 before the consolidation. Over the past year, on a pre-split basis, the shares traded between roughly US$0.72 and US$5.05, a range that captures both how low and how volatile this stock has been.

On profitability, there are encouraging signs alongside lingering caution. In the first quarter of 2026 Curaleaf reported net revenue of US$324 million, up 6 percent and ahead of guidance, with a gross margin of 49 percent, adjusted EBITDA of US$63 million at a 20 percent margin, and net income from continuing operations of US$70 million, or nine cents per share, a swing back into the black. That said, trailing results still reflect prior losses, and the company’s reported earnings on a longer look-back remain negative.

The implication is that Curaleaf is a business showing real operational improvement that the market has not fully rewarded, partly because the sector has burned investors before. The bull case is that rescheduling plus an uplisting unlocks both better profitability and a wider investor base, driving a re-rating. The bear case is that the improvement is fragile, the macro benefits are slow to arrive, and a reverse split is doing some of the heavy lifting on the share price rather than genuine earnings power.

What are the regulatory, debt and execution risks still facing Curaleaf shareholders?

The biggest risk remains regulatory, precisely because the entire thesis depends on it. Rescheduling must be implemented in full, survive any legal or political challenges, and actually deliver the expected tax relief, none of which is guaranteed on a clear timetable. Cannabis remains federally controlled even after rescheduling, so constraints on banking, interstate commerce and uniform national markets persist, and the sector’s fortunes are tightly tied to a policy environment that can shift.

Debt and balance sheet strength are the next concern. In February 2026 Curaleaf refinanced near-term debt by issuing US$500 million of senior secured notes due 2029 at an interest rate of 11.5 percent, a high coupon that reflects how risky lenders still consider cannabis operators. Servicing expensive debt eats into the cash flow that rescheduling is supposed to improve, and the company’s financial strength is rated modestly by independent screens.

Execution and competition round out the picture. The uplisting and US domestication still have to be completed, the international expansion must scale profitably rather than just add low-margin revenue, and rivals such as the other large multi-state operators are equally positioned to benefit from rescheduling, so any sector-wide re-rating would lift competitors too. Insider share-disposition plans and the optics of a reverse split add further caution. None of these is disqualifying, but together they explain why a genuinely improving company still trades at a discount to its potential.

Why do retail investors keep trading the CURLF ticker on every cannabis policy headline?

Cannabis has long been one of the most heavily traded themes among retail investors, and Curaleaf sits near the centre of it. As one of the largest and most recognisable names in the sector, CURLF moves sharply on every policy headline, and rescheduling is exactly the binary, long-awaited catalyst that retail traders have positioned around for years. The stock’s low pre-split price and its over-the-counter listing made it especially accessible to individual investors.

The appeal is a powerful narrative with a clear catalyst calendar. Rescheduling, the reverse split, the planned US uplisting and the European expansion give traders a steady stream of events to react to, and the whole multi-state operator group tends to move together on regulatory news, amplifying the swings. For investors who believe the sector is finally turning a corner, Curaleaf offers scale, brand recognition and a credible international story in one ticker.

The flip side is that this is a sector defined by volatility and disappointment. Cannabis stocks have rallied on policy hopes before only to fall back when reforms stalled, the reverse split itself drew a negative reaction, and the path from rescheduling to actual sustained profits is neither short nor certain. With an uplisting in motion and a shareholder meeting approaching, there is plenty for traders to trade, but anyone treating CURLF as more than a high-risk, policy-driven speculation should weigh just how many times the sector has promised more than it delivered.

Key takeaways for retail investors weighing Curaleaf (OTCQX: CURLF)

• Curaleaf is one of the largest international cannabis companies, operating as a vertically integrated US multi-state operator with a fast-growing European footprint, led by chief executive Boris Jordan.
• US cannabis rescheduling is the central catalyst, because easing the Section 280E tax could dramatically improve profitability across the sector, though full implementation and timing remain uncertain.
• Curaleaf executed a 1-for-3 reverse stock split on 5 June 2026, cutting its subordinate share count to about 233 million, explicitly to prepare for an uplisting onto a major US exchange.
• A planned domestication from British Columbia to Delaware and a shareholder meeting on 22 June 2026 are the next steps in the transition toward US institutional access.
• European growth is doing the heavy lifting, with international revenue up about 35 percent and the full buyout of Germany’s Four 20 Pharma, offsetting a sluggish US market growing only about 2 percent.
• Q1 2026 showed net revenue of US$324 million and net income from continuing operations of US$70 million, but trailing results remain negative and the company carries expensive 11.5 percent debt.
• This is a high-risk, policy-driven cannabis play where a genuine regulatory turning point and concrete corporate action sit alongside federal limits, execution risk and a sector with a history of disappointment.